On Tuesday, a technical advisory panel from the World Health Organization was analyzing data on India’s Covaxin shot against COVID-19, with a decision on its emergency use listing expected soon, according to a spokesperson. The World Health Organization’s technical advisory group requested “more clarifications” from Bharat Biotech for its COVID-19 vaccine Covaxin on Tuesday to undertake a final “risk-benefit assessment” for the vaccine’s Emergency Use Listing.
The technical advisory panel will meet again on November 3 to make a final determination. On April 19, Hyderabad-based Bharat Biotech submitted an EOI (Expression of Interest) to the WHO for Covaxin’s Emergency Use Listing (EUL). On Tuesday, the technical advisory group convened to discuss data. In an email statement, the WHO wrote, “The TAG convened today (October 26, 2021) and agreed that additional clarifications from the manufacturer are needed to undertake a final EUL.
TAG-EUL (Technical Advisory Panel for Emergency Use Listing) is an independent advisory group that advises WHO on whether a Covid 19 vaccine should be listed for emergency use under the EUL method. On COVAXIN, the technical advisory board that analyses all of the evidence for a potential emergency use listing was analyzing that data earlier Tuesday, according to WHO spokesperson Dr Margaret Harris.
To Improve Technical Education, the Bengal government has adopted a three-tier Skilling Plan
A World Health Organization technical advisory group was analyzing data on Covaxin on Tuesday for the emergency use listing of India’s indigenously manufactured vaccine, and if satisfied, a recommendation. The Covaxin is effective against symptomatic COVID-19 in 77.8% of cases and 65.2 per cent of cases against the novel Delta variant in 65.2 per cent of cases. The business announced in June that the final analysis of Covaxin efficacy data from Phase 3 studies had been completed.
The two most extensively used vaccines in India are Covaxin by Bharat Biotech and Covishield by AstraZeneca and Oxford University.
